ERBB2 and breast carcinoma: In humans, overexpression or amplification of HER2 has been reported in 13–20% of breast cancers [2,3], 7–34% of gastric cancers [4], 3–47% of colorectal cancer [5], and 1.9–14.3% of lung carcinomas [6].